We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Glaxo Pays $175 Million To Settle Antitrust Suit Over Relafen Patent

Law360 (February 7, 2004, 12:00 AM EST) -- GlaxoSmithKline has agreed to pay $175 million to settle a lawsuit alleging that the company had violated U.S. antitrust law by blocking generic versions of its Relafen arthritis medicine.

The U.K....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.